Sentences with phrase «in vaccine companies»

Not exact matches

But when they broached the idea of developing such a vaccine with drug companies, nearly all of them said, «No, thank you very much, but we're not interested,» recalls Schiller in a Lasker Foundation interview.

The company first offered this UberHEALTH option two years ago, administering flu shots in Boston, New York, and Washington, D.C. Uber did it again last year, offering vaccines in more than 35 cities — they cost $ 10, but up to 10 people could be vaccinated with each request.

Further gains were mitigated, however, by continued fallout in the company's top - grossing PREVNAR vaccine franchise -LRB--8 %), overseas generic erosion on ENBREL -LRB--20 %), and weak domestic sales of fading blockbuster VIAGRA -LRB--17 %).

The company also has vaccines in clinical development for cholera (Vaxchora), anthrax, HIV and hepatitis A.

Janssen Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which are dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.

Although the company's efforts in this area are still in the early - stage phase, an effective flu vaccine could be worth up to $ 3 billion per year in sales, according to Research and Markets.

The complete wipeout of Novavax's elderly adult RSV vaccine hasn't deterred the company from pursing this multibillion - dollar indication in the least.

If successful, the company's experimental RSV F vaccine could become part of the standard of care for expecting mothers in the United States, and perhaps even abroad.

If the data looks good, it's likely the company's RSV vaccine could be in regulators» hands by 2017.

This is the same company that was fined earlier this year nearly a million dollars for the vaccine related deaths of 14 babies in Argentina.

Democrats and liberal groups have successfully attacked Heck on social security privatization and a vote in the state Senate against a bill that would have required insurance companies to cover a vaccine for cervical cancer.

Germany - based biotech companies CureVac and BioNTech are also testing several mRNA - based cancer vaccines in clinical trials.

The British - American company Acambis, based in Cambridge, Mass., and Cambridge, England, has obtained the license to start production of the vaccine.

At least 12 companies and 17 governments are developing pre-pandemic influenza vaccines in 28 different clinical trials that, if successful, could turn a deadly pandemic infection into a nondeadly one.

One such pseudoscientific claim was that microcephaly is caused by the MMR vaccine and pharmaceutical companies are blaming Zika virus in order to profit from selling Zika vaccines.

In October he started a new company that will work with the pharmaceutical giant Novartis to create next - generation flu vaccines.

The swine flu pandemic was a hoax: scientists, governments and the World Health Organization cooked it up in a vast conspiracy so that vaccine companies could make money.

The team claims its work, funded by Tonix, a pharmaceutical company headquartered in New York City, could lead to a safer, more effective vaccine against smallpox.

The method is relatively new, but far bacteria - based vaccines have proven effective: A seasonal flu vaccine produced by VaxInnate successfully protected humans in clinical trials, and the company's recently tested swine flu vaccine immunized mice against the virus.

In December 2006, Bioniche Life Sciences, a Canadian pharmaceutical company, was granted a license by the Canadian Food Inspection Agency to distribute the vaccine to cattle veterinarians there.

The company's initial vaccine formulation targets Rift Valley Fever, found in Africa and the Arabian Peninsula.

Last January, as new H1N1 flu infections were trailing off in the Northern Hemisphere, accusations began to fly that the World Health Organization's declaration of a pandemic in the spring of 2009 had served mainly to line the pockets of pharmaceutical companies making vaccines and the drug Tamiflu.

The company plans in October to conduct a separate test specifically to study the seasonal flu vaccine's effectiveness among 480 elderly participants (a demographic often encouraged to get seasonal flu shots), and Phase III efficacy trials across a larger set of demographics are scheduled to begin early next year.

The vaccine was most effective against H3N2, increasing antibody titers (a measure how much antibody is produced after vaccination) fourfold in more than 81 percent of who received it, according to the company.

Novavax is not the only company developing VLP - based vaccines, although it is ahead of the game in the category of flu vaccines.

The company claims its VLP approach allows it to manufacture a vaccine to match a particular virus strain in about three months.

In addition, vaccine - makers that use eggs can not begin developing new vaccines that target new virus strains until the U.S. Centers for Disease Control and Prevention (CDC) creates a live - virus reference strain for these companies to work with, a process that could take several weeks.

The company's vaccine approach in both cases is to use viruslike particles (VLPs) containing surface proteins that make the VLPs resemble a virus, thereby eliciting the proper immune response — even though the VLPs lack the genes needed to replicate themselves.

The vaccine is given in three infusions; each costs $ 31,000, for a total treatment tab of $ 93,000, the company said today.

So he joined GSK Vaccines in 2010, as a molecular biologist in the company's Antigen - Specific Cancer Immunotherapeutic program, which aims to harness the immune system for the development of well - tolerated cancer therapies.

The BMJ also notes that three scientists who were involved in the preparation of a 2004 WHO document, WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics, had received payments from pharmaceutical companies, including research funding, or consultancy or speaker fees.

Friedman and colleagues are now in discussions with pharmaceutical companies to move the vaccine, or an optimized version of it, into initial clinical trials.

«A key question will be whether the pharmaceutical companies, which had invested around $ 4 billion in developing the swine flu vaccine, had supporters inside the emergency committee, who then put pressure on WHO to declare a pandemic,» says the article in the BMJ.

And Indian vaccine companies, which can produce vaccine more cheaply, hope to make their own IPV not from wild polio, which is risky to handle, but from the weakened virus used in OPV.

Companies in China and India that had no plans to add IPV to routine childhood vaccines two years ago now do.

The company has begun two safety trials in the US, in people at low risk of infection and in people at high risk, and says it has evidence that the vaccine is safe.

No data on the vaccine have yet been published and some AIDS researchers have privately expressed fears that the company is moving too fast by testing the vaccine in a developing country.

Researchers at MedImmune, a Maryland - based biotech company, and at Washington University in St. Louis whipped up two separate vaccine formulations in the hope that at least one would successfully target an «adhesion» molecule called Filamentous H, or FimH, present on E. coli.

Yet vaccine companies have little incentive to build expensive new factories to make a product that will mostly be used once wild polio is gone — maybe in three years, maybe 10 — and then only for another five years or so.

Already scientists at Human Genome Sciences in Rockville, Maryland — a biotech company affiliated with Venter's research institute — have begun working on a more effective vaccine against Haemophilus.

In order to promote their patented drugs and vaccines against flu, pharmaceutical companies have influenced scientists and official agencies, responsible for public health standards, to alarm governments worldwide.

BRUSSELS — CureVac, a company based in Tübingen, Germany, that develops RNA - based vaccines and therapies, has won a $ 2 million prize awarded by the European Commission to stimulate new vaccine technologies that might help the developing world.

He has long advocated global cooperation in the surveillance of circulating flu viruses to spot emerging new strains so public health officials could plan a response and drug companies could get a head start in making vaccines.

An expert jury says that the company's research could lead to a new generation of vaccines that don't need refrigeration — a massive benefit in many poor countries where power and equipment are in short supply.

In its application, the company showed how stable RNA - based vaccines are.

Jury member Penny Heaton, director of vaccine development at the Bill & Melinda Gates Foundation, said CureVac's RNA technology had «the potential for a large and positive impact on public health,» in a statement released by the company on 10 March.

Several research institutions and companies have vaccine and drug candidates nearly ready to test, but until now a mouse model — a critical stage in preclinical testing — has not been available.

The Swiss - based pharmaceutical company said that it had made 10 liters of vaccine that it will use in pre-clinical studies and maybe early clinical trials.

In a press release issued today, the company said it has yet to receive a «seed stock» from the World Health Organization to manufacture the vaccine and that upon receipt of the stock it will require 4 to 6 months to produce the vaccine.

In November 2012, the company also showed, along with scientists from the Friedrich Loeffler Institute, that the technology could lead to a new generation of flu vaccines.